|
|
NanoVax/NE01 |
|
Vaxjo ID |
181 |
|
Vaccine Adjuvant Name |
NanoVax/NE01 |
|
Adjuvant VO ID |
VO_0005284
|
|
Description |
oil in water emulsion with TLR2/4 agonist that induces mixed Th1/Th17 response |
|
Stage of Development |
Clinical Trial |
|
Location Licensed |
US(Blue Willow Biologics) |
|
Host Species for Testing |
2 |
|
Second Host Species for Testing |
4 |
|
Components |
refined soybean oil, purified water, nonionic detergent, organic solvent and cationic surfactant |
|
Storage |
Can be stored as a bulk or formulated with specific antigens, stable for >3 years at RT and >6 years at 5C |
|
Preparation |
high speed emulsification and diluted to 60% stock containing 3.55% Tween 80, 4.04% ethanol, 37.67% soybean oil, 0.64% cetylpyridinium chloride and 54.1% water. The 60% stock was stored at room temperature (RT)in 2 mL glass vials |
|
Function |
Activation of mucosal and systemic immunity |
| References |
(Costley, 2023): Vaccine Adjuvant Compendium - VAC [https://vac.niaid.nih.gov/view?id=22]
Smith et al., 2019: Smith D, Streatfield SJ, Acosta H, Ganesan S, Fattom A. A nanoemulsion-adjuvanted intranasal H5N1 influenza vaccine protects ferrets against homologous and heterologous H5N1 lethal challenge. Vaccine. 2019; 37(42); 6162-6170. [PubMed: 31495593].
Stanberry et al., 2012: Stanberry LR, Simon JK, Johnson C, Robinson PL, Morry J, Flack MR, Gracon S, Myc A, Hamouda T, Baker JR Jr. Safety and immunogenicity of a novel nanoemulsion mucosal adjuvant W805EC combined with approved seasonal influenza antigens. Vaccine. 2012; 30(2); 307-316. [PubMed: 22079079].
|
|
